Baicalin Induces Apoptotic Death of Human Chondrosarcoma Cells through Mitochondrial Dysfunction and Downregulation of the PI3K/Akt/mTOR Pathway

Abstract

The aim of the present study was to investigate the cytotoxic and antitumour effects of baicalin in human chondrosarcoma both in vivo and in vitro. We examined the effects of baicalin on the growth and apoptosis of human chondrosarcoma cells. Baicalin inhibited the growth of SW1353 and CH2879 cells in a dose- and time-dependent manner, but did not inhibit the growth of normal chondrocytes. Baicalin reduced tumour growth and induced apoptotic death in SW1353-transplanted nude mice without reducing their body weight. Further studies showed that baicalin reduced the mitochondrial membrane potential, upregulated the expression of Bax and cytoplasmic cytochrome c, downregulated the expression of Bcl-2 and mitochondrial cytochromes, and activated caspase-3 and caspase-9. Baicalin inhibited the phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin pathway by decreasing the expression of phosphorylated phosphoinositide 3-kinase, phosphorylated protein kinase B, and phosphorylated mammalian target of rapamycin both in vivo and in vitro. Moreover, the mice that received SC79 and baicalin exhibited a greater tumour size compared with the mice that received baicalin. The mice that received LY294002 and baicalin showed a smaller tumour size compared with the mice that received baicalin. In the in vitro study, SC79 and LY294002 affected the baicalin-induced cytotoxic effects on chondrosarcoma cells in the same manner. Our data suggest baicalin has therapeutic efficacy in human chondrosarcoma through the induction of apoptosis and inhibition of the phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin pathway. Baicalin can be considered a potential therapeutic agent for treating chondrosarcomas.

Key words

chondrosarcoma - Lamiaceae - Scutellaria baicalensis - baicalin - phosphoinositide 3-kinase - antitumour - cytotoxic

• References

• 1 Samuel AM, Costa J, Lindskog DM. Genetic alterations in chondrosarcomas – keys to targeted therapies?. Cell Oncol (Dordr) 2014; 37: 95-105
• 2 Polychronidou G, Karavasilis V, Pollack SM, Huang PH, Lee A, Jones RL. Novel therapeutic approaches in chondrosarcoma. Future Oncol 2017; 13: 637-648
• 3 Lee FY, Mankin HJ, Fondren G, Gebhardt MC, Springfield DS, Rosenberg AE, Jennings LC. Chondrosarcoma of bone: an assessment of outcome. J Bone Joint Surg Am 1999; 81: 326-338
• 4 Jamil N, Howie S, Salter DM. Therapeutic molecular targets in human chondrosarcoma. Int J Exp Pathol 2010; 91: 387-393
• 5 de Jong Y, van Oosterwijk JG, Kruisselbrink AB, Briaire-de Bruijn IH, Agrogiannis G, Baranski Z, Cleven AH, Cleton-Jansen AM, van de Water B, Danen EH, Bovée JV. Targeting survivin as a potential new treatment for chondrosarcoma of bone. Oncogenesis 2016; 5: e222
• 6 Wu J, Ding M, Mao N, Wu Y, Wang C, Yuan J, Miao X, Li J, Shi Z. Celastrol inhibits chondrosarcoma proliferation, migration and invasion through suppression CIP2A/c-MYC signaling pathway. J Pharmacol Sci 2017; 134: 22-28
• 7 Zhao Q, Chen XY, Martin C. Scutellaria baicalensis, the golden herb from the garden of Chinese medicinal plants. Sci Bull (Beijing) 2016; 61: 1391-1398
• 8 Gasiorowski K, Lamer-Zarawska E, Leszek J, Parvathaneni K, Yendluri BB, Błach-Olszewska Z, Aliev G. Flavones from root of Scutellaria baicalensis Georgi: drugs of the future in neurodegeneration?. CNS Neurol Disord Drug Targets 2011; 10: 184-191
• 9 Dinda B, Dinda S, DasSharma S, Banik R, Chakraborty A, Dinda M. Therapeutic potentials of baicalin and its aglycone, baicalein against inflammatory disorders. Eur J Med Chem 2017; 131: 68-80
• 10 Bing-Rong Z, Song-Liang J, Xiao-E C, Xiang-Fei L, Bao-Xiang C, Jie G, Dan L. Protective effect of the Baicalin against DNA damage induced by ultraviolet B irradiation to mouse epidermis. Photodermatol Photoimmunol Photomed 2008; 24: 175-182
• 11 Fang J, Wang H, Zhou J, Dai W, Zhu Y, Zhou Y, Wang X, Zhou M. Baicalin provides neuroprotection in traumatic brain injury mice model through Akt/Nrf2 pathway. Drug Des Devel Ther 2018; 12: 2497-2508
• 12 Gao C, Du Q, Li W, Deng R, Wang Q, Xu A, Shen J. Baicalin modulates APPL2/glucocorticoid receptor signaling cascade, promotes neurogenesis, and attenuates emotional and olfactory dysfunctions in chronic corticosterone-induced depression. Mol Neurobiol 2018; 55: 9334-9348
• 13 Jin J, Chen Y, Wang D, Ma L, Guo M, Zhou C, Dou J. The inhibitory effect of sodium baicalin on oseltamivir-resistant influenza A virus via reduction of neuraminidase activity. Arch Pharm Res 2018; 41: 664-676
• 14 Gong WY, Zhao ZX, Liu BJ, Lu LW, Dong JC. Exploring the chemopreventive properties and perspectives of baicalin and its aglycone baicalein in solid tumors. Eur J Med Chem 2017; 126: 844-852
• 15 Chen H, Gao Y, Wu J, Chen Y, Chen B, Hu J, Zhou J. Exploring therapeutic potentials of baicalin and its aglycone baicalein for hematological malignancies. Cancer Lett 2014; 354: 5-11
• 16 Huang Y, Hu J, Zheng J, Li J, Wei T, Zheng Z, Chen Y. Down-regulation of the PI3K/Akt signaling pathway and induction of apoptosis in CA46 Burkitt lymphoma cells by baicalin. J Exp Clin Cancer Res 2012; 31: 48
• 17 Xu XF, Cai BL, Guan SM, Li Y, Wu JZ, Wang Y, Liu B. Baicalin induces human mucoepidermoid carcinoma Mc3 cells apoptosis in vitro and in vivo . Invest New Drugs 2011; 29: 637-645
• 18 Yu Y, Pei M, Li L. Baicalin induces apoptosis in hepatic cancer cells in vitro and suppresses tumor growth in vivo . Int J Clin Exp Med 2015; 8: 8958-8967
• 19 Huang X, Wu H, Wang L, Zheng L, Zhao J. Protective effects of baicalin on rabbit articular chondrocytes in vitro . Exp Ther Med 2017; 13: 1267-1274
• 20 Gao C, Zhou Y, Li H, Cong X, Jiang Z, Wang X, Cao R, Tian W. Antitumor effects of baicalin on ovarian cancer cells through induction of cell apoptosis and inhibition of cell migration in vitro . Mol Med Rep 2017; 16: 8729-8734
• 21 Romanouskaya TV, Grinev VV. Cytotoxic effect of flavonoids on leukemia cells and normal cells of human blood. Bull Exp Biol Med 2009; 148: 57-59
• 22 Susin SA, Zamzami N, Castedo M, Daugas E, Wang HG, Geley S, Fassy F, Reed JC, Kroemer G. The central executioner of apoptosis: multiple connections between protease activation and mitochondria in Fas/APO-1/CD95- and ceramide-induced apoptosis. J Exp Med 1997; 186: 25-37
• 23 Zamzami N, Brenner C, Marzo I, Susin SA, Kroemer G. Subcellular and submitochondrial mode of action of Bcl-2-like oncoproteins. Oncogene 1998; 16: 2265-2282
• 24 Liu X, Kim CN, Yang J, Jemmerson R, Wang X. nduction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996; 86: 147-157
• 25 Indran IR, Tufo G, Pervaiz S, Brenner C. Recent advances in apoptosis, mitochondria and drug resistance in cancer cells. Biochim Biophys Acta 2011; 1807: 735-745
• 26 Wong WW, Puthalakath H. Bcl-2 family proteins: the sentinels of the mitochondrial apoptosis pathway. IUBMB Life 2008; 60: 390-397
• 27 Takahashi H, Chen MC, Pham H, Angst E, King JC, Park J, Brovman EY, Ishiguro H, Harris DM, Reber HA, Hines OJ, Gukovskaya AS, Go VL, Eibl G. Baicalein, a component of Scutellaria baicalensis, induces apoptosis by Mcl-1 down-regulation in human pancreatic cancer cells. Biochim Biophys Acta 2011; 1813: 1465-1474
• 28 Coffman F, Hamid R, Cohen MC, Garippa R, Cohen S. Biophysical profiling of tumor cell lines. Anal Cell Pathol (Amst) 2011; 34: 225-234
• 29 de Oliveira MR, Nabavi SF, Habtemariam S, Erdogan Orhan I, Daglia M, Nabavi SM. The effects of baicalein and baicalin on mitochondrial function and dynamics: A review. Pharmacol Res 2015; 100: 296-308
• 30 Peng Y, Fu ZZ, Guo CS, Zhang YX, Di Y, Jiang B, Li QW. Effects and mechanism of baicalin on apoptosis of cervical cancer HeLa cells in-vitro . Iran J Pharm Res 2015; 14: 251-261
• 31 Ren X, Zhang Y, Li C, Wang H, Jiang Z, Zhang Z, Guo Q, Song G, Bi K, Jiang G. Enhancement of baicalin by hexamethylene bisacetamide on the induction of apoptosis contributes to simultaneous activation of the intrinsic and extrinsic apoptotic pathways in human leukemia cells. Oncol Rep 2013; 30: 2071-2080
• 32 Spangle JM, Roberts TM, Zhao JJ. The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer. Biochim Biophys Acta 2017; 1868: 123-131
• 33 Chang W, Wu QQ, Xiao Y, Jiang XH, Yuan Y, Zeng XF, Tang QZ. Acacetin protects against cardiac remodeling after myocardial infarction by mediating MAPK and PI3K/Akt signal pathway. J Pharmacol Sci 2017; 135: 156-163
• 34 Chen G, Yue Y, Qin J, Xiao X, Ren Q, Xiao B. Plumbagin suppresses the migration and invasion of glioma cells via downregulation of MMP-2/9 expression and inaction of PI3K/Akt signaling pathway in vitro . J Pharmacol Sci 2017; 134: 59-67
• 35 Kim KY, Park KI, Kim SH, Yu SN, Park SG, Kim YW, Seo YK, Ma JY, Ahn SC. Inhibition of autophagy promotes salinomycin-induced apoptosis via reactive oxygen species-mediated PI3K/AKT/mTOR and ERK/p38 MAPK-dependent signaling in human prostate cancer cells. Int J Mol Sci 2017; 18: pii:E1088
• 36 Liang G, Liu M, Wang Q, Shen Y, Mei H, Li D, Liu W. Itraconazole exerts its anti-melanoma effect by suppressing Hedgehog, Wnt, and PI3K/mTOR signaling pathways. Oncotarget 2017; 8: 28510-28525
• 37 Bai R, Ding T, Zhao J, Liu S, Zhang L, Lan X, Yu Y, Yin L. The effect of PI3K inhibitor LY294002 and gemcitabine hydrochloride combined with ionizing radiation on the formation of vasculogenic mimicry of Panc-1 cells in vitro and in vivo . Neoplasma 2016; 63: 80-92
• 38 Davies BR, Greenwood H, Dudley P, Crafter C, Yu DH, Zhang J, Li J, Gao B, Ji Q, Maynard J, Ricketts SA, Cross D, Cosulich S, Chresta CC, Page K, Yates J, Lane C, Watson R, Luke R, Ogilvie D, Pass M. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther 2012; 11: 873-887
• 39 Vier J, Groth M, Sochalska M, Kirschnek S. The anti-apoptotic Bcl-2 family protein A1/Bfl-1 regulates neutrophil survival and homeostasis and is controlled via PI3K and JAK/STAT signaling. Cell Death Dis 2016; 7: e2103
• 40 Zuo D, Lin L, Liu Y, Wang C, Xu J, Sun F, Li L, Li Z, Wu Y. Baicalin attenuates ketamine-induced neurotoxicity in the developing rats: Involvement of PI3K/Akt and CREB/BDNF/Bcl-2 pathways. Neurotox Res 2016; 30: 159-172
• 41 Zheng J, Hu JD, Chen YY, Chen BY, Huang Y, Zheng ZH, Liu TB. Baicalin induces apoptosis in leukemia HL-60/ADR cells via possible down-regulation of the PI3K/Akt signaling pathway. Asian Pac J Cancer Prev 2012; 13: 1119-1124
• 42 Li X, Zou K, Gou J, Du Q, Li D, He X, Li Z. Effect of baicalin-copper on the induction of apoptosis in human hepatoblastoma cancer HepG2 cells. Med Oncol 2015; 32: 72
• 43 Huo XK, Wang B, Zheng L, Cong HJ, Xiang T, Wang SM, Sun CP, Wang C, Zhang L, Deng S, Wu B, Ma XC. Comparative pharmacokinetic study of baicalin and its metabolites after oral administration of baicalin and Chaiqin Qingning capsule in normal and febrile rats. J Chromatogr B Analyt Technol Biomed Life Sci 2017; 1059: 14-20
• 44 Liu W, Jing ZT, Wu SX, He Y, Lin YT, Chen WN, Lin XJ, Lin X. A novel AKT activator, SC79, prevents acute hepatic failure induced by Fas-mediated apoptosis of hepatocytes. Am J Pathol 2018; 188: 1171-1182
• 45 Meng X, Zhang Q, Zheng G, Pang R, Hua T, Yang S, Li J. Doxorubicin combined with celecoxib inhibits tumor growth of medullary thyroid carcinoma in xenografted mice. Oncol Lett 2014; 7: 2053-2058